Nineteengale Therapeutics is a new joint venture that was launched to fill a large void. Cyclica Inc., along with its partner, Neurotheryx Canada Ltd., both of Toronto, created Nineteengale to find and develop cannabinoid-inspired drugs for bipolar disorder, anxiety and pain management.
Beta-O2 Technologies Ltd. plans to enroll its first patients in clinical trials for its second-generation bio-artificial pancreas, ßAir, in the coming months. The small, implantable titanium device has separate components that hold pancreatic cells and a rechargeable oxygen tank. Beta-O2 is based in Rosh-Haayin, Israel.
Lessons learned from development of hepatitis C therapies could be applied to the underserved hepatitis B population, potentially leading to a functional cure through a combination of optimized drugs that attack the virus from different angles. That is the mission of 2-year-old Aligos Therapeutics Inc., a South San Francisco-based startup focused on liver-related diseases.
Tony McKinney, the founder and CEO of Ethismos Research Inc., has worked with the small molecule he plans to take into the clinic this year for the past 10 years. All the while he’s used the same support group of personnel to develop the molecule. Sometimes that group works and sometimes it’s on hiatus.
BOGOTA, Colombia – Ziptek Mexico, from Hermosillo, Mexico, is working to revolutionize the sutures market with an innovative product that is already making its way to the U.S. surgical orthopedic device market. Plans to expand across Latin America are progressing.
Looking to help blind and visually impaired patients, Envision, of The Hague, Netherlands, has unveiled its plans to integrate its artificial intelligence (AI)-powered software technology into Google Glass.
Palvella Therapeutics Inc. has completed enrollment of its phase II/III trial for treating adults with pachyonychia congenita, a rare disease that eventually leads patients to a life of chronic pain and severe problems with walking.
Orionis Biosciences Inc. has begun a four-year collaboration with Novartis AG to discover and design small-molecule therapeutics such as protein degraders that target several therapeutic areas, including cancer. The agreement’s terms include research funding a convertible note investment, royalties and potential clinical milestones.
HONG KONG – MBD Co. Ltd. and Azothbio Inc., both based in South Korea, have entered an agreement for rare cancer drug development using an AI-powered drug discovery platform.
Aivita Biomedical Inc.’s CEO, Hans Keirstead, just finished up a $12.5 million fundraiser and he’s prepping for another $12.5 million in a second effort. In the two months since he started raising the money, he has hired four more people and plans to hire four more by year-end, bringing the company’s headcount to 36 employees.
RSS
